Announcements

Resignation of Non-Executive Director-Nathalie Leitch

Outcome of Board Meeting 10th May 2024

Intimation of PCC Judicial order

USFDA- Lexington Facility

Annual Secretarial Compliance Report for the year ended 31st March, 2023

US FDA – Riverview Facility

Outcome of the Board Meeting for the Unaudited Financial Results for the quarter and nine months ended 31st December, 2023.

PPL – Board Meeting Intimation – 30th January 2024

Press Release – Intimation of Press Release regarding launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP

Intimation of Schedule of Analyst/Investor Meet dated 8th to 10th January 2024

Press Release – Intimation of a Press Release regarding opening of Antibody-Drug Conjugate (“ADC”) manufacturing expansion in Grangemouth, Scotland

Details of Litigation as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – VetDC

Intimation of Schedule of Analyst/Investor Meet dated 12th December 2023 and 18th December 2023

PPL – US FDA Inspection closure – Bethlehem

PPL – Details of Litigation as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Intimation of Schedule of Analyst/Investor Meet dated 05th December 2023

Intimation of Schedule of Analyst/Investor Meet dated 7th to 8th November, 2023

PPL – Newspaper Advertisement – Extract of the Consolidated Financial Results for the quarter and half year ended 30th September 2023

Outcome of the Board Meeting for the Unaudited Financial Results for the quarter and half year ended 30th September, 2023.

Intimation of Schedule of Analyst/Investor Meet dated 30th October 2023

PPL – Board Meeting Intimation – 27th October 2023

Press Release – Intimation of a Press Release regarding In-Vitro Biology Capabilities at the Ahmedabad Discovery Services Site of the Company

PPL – US FDA Inspection – Bethlehem, USA

PPL – Reg 30 – Voluntary liquidation of subsidiary

Intimation of Schedule of Analyst/Investor Meet

PPL – Newspaper Advertisement – Extract of Consolidated Financial Results for the quarter ended 30th June, 2023

PPL – Newspaper Advertisement – Extract of Consolidated Financial Results for the quarter and year ended 31st March, 2023

Intimation of Schedule of Analyst/ Institutional Investor Meet

Outcome of Committee of Directors (Rights Issue) meeting

Press Release and Investor presentation – 03.08.2023

Outcome of the Board Meeting for the Unaudited financial results for quarter ended 30th June, 2023.

Grant of stock options pursuant to Piramal Pharma Limited – Employee Stock Option and Incentive Plan 2022 (‘Plan 2022’)

PPL – Board Meeting Intimation -3rd August, 2023

Outcome of Rights Issue Committee Meeting

Intimation of Rights Issue Committee Meeting

PPL-Newspaper Advertisement- Information regarding 3rd Annual General Meeting (‘AGM’)

PPL- Press Release – Appointment of Mr. Jeffrey Hampton as President & Chief Operating Officer of Piramal Critical Care.

Intimation of Annual General Meeting

PPL – US FDA Inspection – Pithampur facility

PPL – Reg 30 – Outcome of Board meeting

PPL- Board Meeting Intimation – 24th May, 2023

PPL – US FDA Inspection – Sellersville, USA Facility

PPL – US FDA Inspection – Digwal facility

PPL – Intimation of Credit Rating

PPL- Reg 30 – Outcome of Board Meeting.

PPL- Declaration of Voting Results of Postal ballot

PPL- Newspaper advertisement of Postal Ballot Notice

PPL-Stock Exchange intimation – Submission of Postal Ballot Notice.

PPL Postal Ballot Notice – February, 2023

PPL-Newspaper Advertisement – Extract of Consolidated Financial Results for the quarter and nine months ended 31st December, 2022

PPL-Newspaper Advertisement – Extract of Consolidated Financial Results for the quarter and half year ended 30th September, 2022

Auditors Report with UDIN for quarter and nine months ended 30th December, 2022

PPL – Outcome of Board meeting – 08th February, 2023

Receipt of request seeking reclassification from ‘ Promoter group’ category to ‘Public’ category of Piramal Pharma Limited

PPL – Update on Board Meeting Intimation – 08th February, 2023

PPL – Board meeting Intimation – 8th February, 2023

US FDA Inspection – Sellersville

US FDA Inspection – Lexington

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Related Party Transaction – 30th September, 2022

PPL – Newspaper Advertisement – Extract of Consolidated Financial Results for the Quarter and Half year ended 30th September, 2022

Auditors Report with UDIN for quarter and half year ended 30th September, 2022

PPL – Outcome of Board Meeting – 08th November, 2022

Intimation of Schedule of Analyst Call

US FDA inspection Riverview

PPL – Intimation of Contact Details of Key Managerial Personnel for determining materiality of Event/making disclosures to Stock Exchange

PPL – Board Meeting Intimation – 8th November, 2022